arrow
K

Kelly Chin

university of texas
H指数:37
被引数:7,552

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Characteristics, Treatment Patterns and Outcomes of Patients with Pulmonary Arterial Hypertension by Race and Ethnicity Using Real-World Data from the Combined OPUS/OrPHeUS Studies

肺动脉高压患者按种族和族裔划分的特征、治疗模式与结局:使用Combined OPUS/OrPHeUS研究中的真实世界数据

2025-11-190
OAAI
Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study

Seralutinib治疗成人肺动脉高压:TORREY开放标签扩展研究

2025-08-110
OA
Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity

接受塞来昔帕治疗的肺动脉高压患者特征:SPHERE登记研究按种族和族裔分析

2025-08-040
OAAI
Corrigendum to ‘‘Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)’’ [J Heart Lung Transplant 43 (2024) 272–283]

勘误:“接受西洛他唑治疗的真实世界肺动脉高压患者疾病特征、治疗及结局:来自SPHERE登记研究(SelexiPag: tHe usErs dRug rEgistry)”[J Heart Lung Transplant 43 (2024) 272–283]

2025-05-140
OAAI
Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in patients with pulmonary arterial hypertension: A post-hoc analysis of the GRIPHON study

REVEAL Lite 2风险状态的变化与肺动脉高压患者的长期预后相关: GRIPHON研究的事后分析

2024-12-010
PRE
Sustained benefit with seralutinib treatment: Lessons from the open-label extension (OLE) of the TORREY study
2024-10-300
PRE
Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities

在有和没有心脏合并症的肺动脉高压患者中,使用马西坦和他达拉非进行初始联合治疗

2024-07-051
OAAI